Pfizer Inc. (PFE) - 5i Research

Pfizer Inc. (PFE $27.83)
- $27.83 P/E (TTM): 20.82X Cap: $161.09B
- View PFE Profile
- View Questions on PFE

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Bristol-Myers Squibb Company (BMY $59.33)
- $59.33 P/E (TTM): 17.23X Cap: $121.13B
- View BMY Profile
- View Questions on BMY
Kimberly-Clark Corporation (KMB $96.99)
- $96.99 P/E (TTM): 15.84X Cap: $32.19B
- View KMB Profile
- View Questions on KMB
Merck & Company Inc. (MRK $120.85)
- $120.85 P/E (TTM): 16.6X Cap: $298.78B
- View MRK Profile
- View Questions on MRK
Pfizer Inc. (PFE $27.83)
- $27.83 P/E (TTM): 20.82X Cap: $161.09B
- View PFE Profile
- View Questions on PFE
Procter & Gamble Company (The) (PG $142.77)
- $142.77 P/E (TTM): 21.2X Cap: $331.79B
- View PG Profile
- View Questions on PG
Philip Morris International Inc (PM $160.34)
- $160.34 P/E (TTM): 21.78X Cap: $249.59B
- View PM Profile
- View Questions on PM
Williams Companies Inc. (The) (WMB $72.59)
- $72.59 P/E (TTM): 33.64X Cap: $88.76B
- View WMB Profile
- View Questions on WMB
Rio Tinto Plc (RIO $94.01)
- $94.01 P/E (TTM): 15.53X Cap: $118.07B
- View RIO Profile
- View Questions on RIO
VICI Properties Inc. (VICI $27.66)
- $27.66 P/E (TTM): 10.6X Cap: $29.56B
- View VICI Profile
- View Questions on VICI
Nestle SA ADR (NSRGY $98.56)
- $98.56 P/E (TTM): 1.77X Cap: $258.36B
- View NSRGY Profile
- View Questions on NSRGY
Amcor plc (AMCR $39.81)
- $39.81 P/E (TTM): 26.13X Cap: $18.80B
- View AMCR Profile
- View Questions on AMCR
JPMorgan Equity Premium Income ETF (JEPI $56.70)
- $56.70 P/E (TTM): 25.63X Cap: $43.68B
- View JEPI Profile
- View Questions on JEPI
Verizon CDR (CAD Hedged) (VZ $20.83)
- $20.83 P/E (TTM): 12.17X Cap: $294.89B
- View VZ Profile
- View Questions on VZ

Q: Hi . Looking for your favourite US/International dividend payers is USD. Can you make 5 or 6 suggestions?

Read Answer Asked by Rachel on March 16, 2026

Regeneron Pharmaceuticals Inc. (REGN $763.04)
- $763.04 P/E (TTM): 18.37X Cap: $80.66B
- View REGN Profile
- View Questions on REGN
AbbVie Inc. (ABBV $206.69)
- $206.69 P/E (TTM): 88.49X Cap: $369.38B
- View ABBV Profile
- View Questions on ABBV
Merck & Company Inc. (MRK $120.85)
- $120.85 P/E (TTM): 16.6X Cap: $298.78B
- View MRK Profile
- View Questions on MRK
Pfizer Inc. (PFE $27.83)
- $27.83 P/E (TTM): 20.82X Cap: $161.09B
- View PFE Profile
- View Questions on PFE
Zoetis Inc. Class A (ZTS $118.26)
- $118.26 P/E (TTM): 19.59X Cap: $49.92B
- View ZTS Profile
- View Questions on ZTS

Q: Please rank these pharma stocks for a new buy and suggest any you may prefer. Thank you.

Read Answer Asked by Ken on February 18, 2026

Merck & Company Inc. (MRK $120.85)
- $120.85 P/E (TTM): 16.6X Cap: $298.78B
- View MRK Profile
- View Questions on MRK
Pfizer Inc. (PFE $27.83)
- $27.83 P/E (TTM): 20.82X Cap: $161.09B
- View PFE Profile
- View Questions on PFE

Q: Given the sector's relative under performance, I believe the timing is right to increase my portfolio weighting in the Healthcare Sector. I own MRK and PFE. As I started to research individual companies it became apparent my lack of expertise in the area and the pace of technological advance makes stock picking in this area challenging. As such I'm considering an ETF and am currently looking at RSPH. Do you agree with the timing and would you advise an ETF or another individual company? If the former, what do you think of RSPH and if the latter' what would recommend for global exposure to the sector

Thank-you

Any input appreciated,

Read Answer Asked by jeff on February 02, 2026